176 related articles for article (PubMed ID: 11763308)
1. Lipid lowering in high-risk populations: how low should we go?
Watson K
Ethn Dis; 2001; 11(4):834-7. PubMed ID: 11763308
[No Abstract] [Full Text] [Related]
2. [The role of lipid metabolism in the prevention of coronary heart disease].
Mathes P; Thiery J
Z Kardiol; 2005; 94 Suppl 3():III/43-55. PubMed ID: 16258792
[TBL] [Abstract][Full Text] [Related]
3. Implications of 4S evidence on baseline lipid levels.
Jacobson TA
Lancet; 1995 Jul; 346(8968):181-2. PubMed ID: 7603245
[No Abstract] [Full Text] [Related]
4. Lipid analysis in an aging population.
Pallazola VA; Sathiyakumar V; Martin SS
Aging (Albany NY); 2019 Feb; 11(4):1073-1074. PubMed ID: 30733425
[No Abstract] [Full Text] [Related]
5. A symposium: lipid management summit on improving practice outcome. Introduction.
Ballantyne CM
Am J Cardiol; 2000 Feb; 85(3A):1A-2A. PubMed ID: 10695700
[No Abstract] [Full Text] [Related]
6. Trials of lipid-lowering therapy in primary prevention of coronary heart disease.
Jones PH
Curr Opin Lipidol; 1995 Dec; 6(6):365-8. PubMed ID: 8750249
[TBL] [Abstract][Full Text] [Related]
7. Pro and con: high-density lipoprotein, triglycerides, and other lipid subfractions are the future of lipid management.
Assmann G
Am J Cardiol; 2001 Mar; 87(5A):2B-7B. PubMed ID: 11256848
[TBL] [Abstract][Full Text] [Related]
8. Achievement of low-density lipoprotein cholesterol goals: new strategies to address new guidelines.
Illingworth DR
Cardiol Clin; 2003 Aug; 21(3):363-75. PubMed ID: 14621451
[TBL] [Abstract][Full Text] [Related]
9. Niacin as a component of combination therapy for dyslipidemia.
Miller M
Mayo Clin Proc; 2003 Jun; 78(6):735-42. PubMed ID: 12934785
[TBL] [Abstract][Full Text] [Related]
10. Implications of 4S evidence on baseline lipid levels.
Durrington PN
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7661979
[No Abstract] [Full Text] [Related]
11. Effects of lipid lowering on coronary plaques and coronary events.
Roberts WC
Am J Cardiol; 1997 Oct; 80(8B):8H-9H. PubMed ID: 9372992
[No Abstract] [Full Text] [Related]
12. Implications of 4S evidence on baseline lipid levels.
Ravnskov U
Lancet; 1995 Jul; 346(8968):181. PubMed ID: 7603244
[No Abstract] [Full Text] [Related]
13. Hypolipidemic drugs in coronary artery disease.
Bittar GB
Ann Intern Med; 1997 Jun; 126(11):916-7. PubMed ID: 9163300
[No Abstract] [Full Text] [Related]
14. A case for lipid-lowering?
Durrington P
Diabet Med; 2000 Sep; 17 Suppl 2():4-5. PubMed ID: 11048824
[No Abstract] [Full Text] [Related]
15. Rationale for treatment.
Gotto AM
Am J Med; 1991 Jul; 91(1B):31S-36S. PubMed ID: 1867234
[TBL] [Abstract][Full Text] [Related]
16. Secondary prevention in a cardiology group practice and hospital setting after a heart-care initiative.
LaBresh KA; Owen P; Alteri C; Reilly S; Albright PS; Hordes AR; Shaftel PA; Noonan TE; Stoukides CA; Kaul AF
Am J Cardiol; 2000 Feb; 85(3A):23A-29A. PubMed ID: 10695704
[TBL] [Abstract][Full Text] [Related]
17. Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group.
Schrott HG; Bittner V; Vittinghoff E; Herrington DM; Hulley S
JAMA; 1997 Apr 23-30; 277(16):1281-6. PubMed ID: 9109465
[TBL] [Abstract][Full Text] [Related]
18. Primary prevention of ischaemic heart disease with lipid-lowering drugs.
Lancet; 1988 Feb; 1(8581):333-4. PubMed ID: 2893141
[No Abstract] [Full Text] [Related]
19. Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets.
Rosenson RS
Postgrad Med; 2005 Apr; 117(4):17-20, 23-7. PubMed ID: 15842129
[TBL] [Abstract][Full Text] [Related]
20. [How to manage lipid profiles and their interpretation in patients with coronary heart disease?].
Farnier M
Presse Med; 2009 Jun; 38(6):958-63. PubMed ID: 19376680
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
